STAT3 and gastric cancer: We have showed that omeprazole suppressed De novo lipogenesis (DNL) in gastric cancer cells by inhibition of fatty acid synthase (FASN) and acetyl-CoA carboxylase (ACCA) [10], while Rabeprazole was demonstrated to inhibit cell proliferation by targeting signal transducer and activator of transcription 3 (STAT3)-mediated HK2 expression [11].